Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 63,230

Document Document Title
WO/2019/136558A1
Inhibition of indoleamine 2,3-dioxygenase (IDOl) is an attractive immunotherapeutic approach for the treatment of a variety of cancers. Dysregulation of this enzyme has also been implicated in other severe diseases such as Alzheimer's di...  
WO/2019/140417A1
Amines and amine derivatives that improve the buffering range, and / or reduce the chelation and other negative interactions of the buffer and the system to be buffered. Aminopyridines channel blocking, combined with buffering and zwitte...  
WO/2019/099777A3
Provided herein are compounds and methods for modulating abnormal repeat expansions of gene sequences. More particularly, provided are inhibitors of RNA and the uses of such inhibitors in regulating nucleotide repeat expansions, e.g., to...  
WO/2019/138424A1
The present invention relates to pharmaceutical compositions comprising Lenalidomide. More particularly, the present invention relates to a stable composition comprising anhydrous Lenalidomide Form I and one or more pharmaceutically acce...  
WO/2019/140387A1
The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of CRBN, and the treatment of CRBN-mediated disorders.  
WO/2019/139233A1
The present invention provides a novel heterocyclic compound and an organic light emitting element using the same.  
WO/2019/140380A1
The present invention provides compounds, compositions thereof, and methods of using the same for the targeted degradation of proteins, and the treatment of target protein-mediated disorders.  
WO/2019/137985A1
The present invention relates to a novel class of tetrahydroisoquinoline compounds of formula I and to compositions comprising the same. The compounds and compositions of the present invention can be used as medicaments in the treatment ...  
WO/2019/135920A1
The present invention relates to metallo-β-lactamase inhibitor compounds of Formula I: and pharmaceutically acceptable salts thereof, wherein RA, R1, and Z are as defined herein. The present invention also relates to compositions which ...  
WO/2019/134680A1
The present invention relates to a fused ring compound having the structure represented by formula I, a pharmaceutically acceptable salt thereof, a stereoisomer thereof, a solvate thereof, or a prodrug molecule thereof. The novel fused r...  
WO/2018/111315A8
Disclosed herein are compounds of the formulas: as well as analogs thereof, wherein the variables are defined herein. Also provided are pharmaceutical compositions thereof. In some aspects, the compounds and compositions provided herein ...  
WO/2019/136016A1
Provided herein are isotopologues of Compound A, which are enriched with isotopes such as, for example, deuterium. Pharmaceutical compositions comprising the isotope-enriched compounds, and methods of using such compounds are also provided.  
WO/2019/134707A1
Provided are a compound as presented in formula (I), a tautomer and enantiomer thereof, or a pharmaceutically acceptable salt, a cristal form, a hydrate or a solvate thereof. The compound of formula (I) can be effectively combined with S...  
WO/2019/135254A1
The present invention discloses Novel polymorphs of Apalutamide and process for their preparation. The present invention further disclose processes for the preparation of amorphous and amorphous solid dispersion of Apalutamide. Formula (I).  
WO/2019/104062A8
The present invention relates to new polymorphs of LXRβ agonists which exhibit improved physical properties. The invention also relates to pharmaceutical compositions including a pharmaceutically effective amount of an LXRβ agonist, as...  
WO/2019/134082A1
Disclosed herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof. The compounds function as inhibitors of MTH1. Preferred compounds are useful in the treatment of cancer or other diseases, where inhibition of M...  
WO/2019/134662A1
The present invention relates to a type of isoindolinone derivatives and use thereof in the preparation of a medicament for treating diseases associated with a novel colony stimulating factor 1 receptor (CSF-1R) inhibitor. In particular,...  
WO/2019/134661A1
The present invention relates to a type of isoindolinone derivatives and use thereof in the preparation of a medicament for treating diseases associated with a novel colony stimulating factor 1 receptor (CSF-1R) inhibitor. In particular,...  
WO/2019/128343A1
Provided are an electroluminescent material and the use thereof in photoelectric devices. The material has a structure as shown by formula (I), wherein Ar is one of formulae (II) and (III), and wherein R 1 and R 2 are independently selec...  
WO/2019/132483A1
The present specification relates to a heterocyclic compound represented by chemical formula 1 and an organic light emitting element comprising the same.  
WO/2019/128871A1
Disclosed are an N-alkyl-N-cyanoalkylbenzamide compound: general formula (I), and an intermediate with general formula (II) used for preparing the compound, wherein: R1 is selected from halogen or C1-C3alkyl; R2 is selected from halogen ...  
WO/2019/131695A1
The present invention relates to methods for producing 5-(2-fluorophenyl)-1H-pyrrole-3-carboxyaldehyde by formylation and deprotection and producing 1-[5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-y l]-N-methylmethanamine mono...  
WO/2019/133605A1
Provided herein is a novel process for the preparation of an amino-pyrimidine and salts thereof. Also provided herein are novel intermediates used in this process and their preparation.  
WO/2019/131798A1
Provided is a cell growth inhibitor containing, as an active ingredient, a compound represented by general formula (1) below, or a pharmacologically acceptable salt thereof. [In general formula (1), J1 and J2 represent CH or N, but both ...  
WO/2019/126842A1
The present invention relates to compounds useful in the modulation of ion channel activity in cells. The invention also relates to use of these compounds in the treatment of pain, and pharmaceutical compositions containing these compoun...  
WO/2019/131458A1
Provided are a compound represented by formula (1) or a salt thereof, and a medicine including the same. [In the formula, X1 represents a hydrogen atom or a halogen atom, X2 represents a fluorine atom or a nitrile group, and X3 represent...  
WO/2019/128872A1
Disclosed are a pyrazole amide compound-benzamide compound of general formula (I) having a pesticidal activity, and an intermediate of general formula (II) used for preparing the compound of general formula (I), wherein R1 is selected fr...  
WO/2019/132492A1
The present specification relates to a heterocyclic compound represented by chemical formula 1 and an organic light emitting device comprising the same.  
WO/2019/120121A1
Disclosed are a diphenylaminopyrimidine compound having an inhibitory effect on protein tyrosine kinase, pharmaceutically acceptable salts, crystal forms, prodrugs, metabolites, hydrates, solvates, stereoisomers or isotope derivatives th...  
WO/2019/119206A1
Provided herein is compounds of formulas (Ia) and (Ib) which are PI3K-delta inhibitors, and uses for the treatment of PI3K-delta-mediated diseases such as inflammation, asthma, COPD and cancer.  
WO/2019/126106A1
The present invention relates to compounds and methods useful for modulation, e.g. inhibition, of C-X-C receptor type 4 (CXCR4). The invention also provides pharmaceutically acceptable compositions comprising compounds of the present inv...  
WO/2019/119141A1
The present application is directed to compounds of Formula (I): compounds of Formula (II): compounds of Formula (III): and compounds of Formula (IV): compositions comprising these compounds and their uses, for example as medicaments and...  
WO/2019/121108A1
The invention relates to an organic compound, in particular for the application in optoelectronic devices. According to the invention, the organic compound consists of - one first chemical moiety with a structure of formula I, and - one ...  
WO/2019/126731A1
The invention relates to inhibitors of PI5P4K inhibitors useful in the treatment of cancers, neurodegenerative diseases, inflammatory disorders, and metabolic diseases, having the Formula: (I) where A, B, R1, X1, X2, and W are described ...  
WO/2019/126733A1
The invention relates to inhibitors of PI5P4K inhibitors useful in the treatment of cancers, neurodegenerative diseases, inflammatory disorders, and metabolic diseases, having the Formula (I): wherein A, X, Y, Z, Q, R1, R2, R3, R4, R5, a...  
WO/2019/125185A1
The invention provides novel quinoline sulfonamide compounds of Formula I: (Formula (I)) and their use for the treatment or prevention of bacterial infections caused by both Gram positive and Gram negative bacteria such as, for example, ...  
WO/2019/121606A1
The invention relates to compounds according to general formula (I), which act as modulators of the glucocorticoid receptor and can be used in the treatment and/or prophylaxis of disorders which are at least partially mediated by the glu...  
WO/2019/126094A1
The present invention provides compounds of Formula (I): Formula (I) or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein all the variables are as defined herein. These compounds are selective LPA ...  
WO/2019/122418A1
The present disclosure relates to biguanide derivatives of formula (I) and their rearrangement products. The present disclosure also relates to the use of these compounds in a method for treating cancer, in particular melanoma.  
WO/2019/120125A1
The present invention relates to a composition for preparing an organic electronic device. The composition comprises at least two organic functional materials H1 and H2, and at least one organic solvent, in which: 1) H1 and H2 form a typ...  
WO/2019/121691A1
The present disclosure relates to compounds of Formula (I): (I) and to their pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are useful for...  
WO/2019/121649A1
The present invention relates to a method of separating racemic nicotine of Formula (l-a) as a mixture of the (R)- and (S)-enantiomers into the enantiomerically pure (S)- and (R)-nicotine represented by Formula (l-b) and (l-c), by adding...  
WO/2019/119144A1
The present application relates to compounds of Formula I (I) or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, to compositions comprising these compounds or pharmaceutically acceptable salts, solvates and/or prodru...  
WO/2019/123194A1
The present invention provides novel anthranilamides of Formula I, wherein, the definition of W1, W2, D, Z1, E, R1, R2, R3, R4, m is as described in the description. The present invention also relates to the composition, combination, use...  
WO/2019/126253A1
Disclosed are compounds of Formula (I) or salts thereof, wherein A, G, R1, R5, and n are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, or 8, or 9, and pharmace...  
WO/2019/099868A3
Pharmaceutical Degraders and Degrons for use in therapeutic applications are described herein.  
WO/2019/125849A1
The present invention provides for the treatment of disorders related to TLR7/8 overexpression or abherrant activation, wherein the disorder is selected from multiple sclerosis, Alzheimer's Disease, myositis, stroke, ischemia, CNS neurop...  
WO/2019/122265A1
The present application relates to compounds of formula (I') or formula (I), such as formula (Ia), and their pharmaceutical compositions/preparations. This application further relates to methods of treating or preventing neurodegenerativ...  
WO/2019/119207A1
Provided are compounds of formula (I) which are PI3K-delta inhibitors, and as such are useful for the treatment of PI3K-delta-mediated diseases such as inflammation, asthma, COPD and cancer.  
WO/2019/126090A1
The present invention provides compounds of Formula (I): Formula (I), or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein all the variables are as defined herein. These compounds are selective LPA...  

Matches 1 - 50 out of 63,230